SEATTLE – Phase Genomics, Inc., a leading innovator at the forefront of genomics technology development, today announced the appointment of David Shoultz, PhD, MBA as the company’s first Chief Business Officer. A strategic addition to the executive suite, Shoultz will drive growth as Phase Genomics accelerates market awareness and its work to amplify the... Read more »

  Data shows proprietary technology enables lower cost and higher efficacy through new induced-dysbiosis vaccine targeting a parasite’s microbiome   The salmon aquaculture industry has – to put it mildly – a lousy problem.    Sea lice have been sucking salmon dry at facilities across Europe and the Americas at a rate of more than... Read more »

  SEATTLE (March, 4, 2024) – Phase Genomics, Inc., a leading innovator at the forefront of genomics technology development, today announced $1.5MM in new funding from the Bill & Melinda Gates Foundation to fuel a new antimicrobial discovery platform. Leveraging the power of lysins, phage-derived proteins that selectively kill specific bacteria and archaea, the program... Read more »

  Decades of antibiotic use – and abuse – are triggering a global rise in antibiotic resistance and limiting the usefulness of these life-saving drugs. In a nod to the adage, “The enemy of my enemy is my friend,” a solution may lie with bacteria’s oldest adversary: phages, the viruses that prey upon them. Our... Read more »

  New genomic technology reveals the parental past of “ancient asexuals,” paving a route to crop engineering and soil remediation with symbiotic fungi   In a warming, crowded world, we need more help than ever from plants. But maximizing the bounty from crops — from food to fuel to fibers — means coaxing plants to... Read more »

  Another year has flown by with great accomplishments and advancements from researchers around the world wielding the latest in proximity ligation technology. As the year draws to a close, we at Phase Genomics would like to highlight some of the milestones that have been crossed in 2023 before setting our sights on an even... Read more »

  $2.5M in funding from the National Cancer Institute and Andy Hill CARE Fund will accelerate Phase Genomics’ proprietary OncoTerra™ platform toward clinical use, unlocking new genome-wide cytogenetic insights for acute myeloid leukemia and colorectal cancer   Monday, August 7, 2023   SEATTLE– Phase Genomics, Inc. a leading developer of cutting-edge genomic solutions, today announced... Read more »

Hydrothermal mat sampling aboard R/V Roger Revelle using ROV Jason. Credit: R/V Roger Revelle, Scripps institute of Oceanography.   For decades, biologists largely studied microbes and their viruses in isolation, nurtured in laboratory cultures. Yet, to paraphrase the poet John Donne, no microbe is an island. In recent years, scientists have recognized this by studying... Read more »

  With 2023 well under way, here is a quick glimpse into the rearview mirror of Phase Genomics in 2022.   Last year was an exciting one for those of us in the genomics space. Exploring genomic interactions and refining methods to assemble the most complete genomes, the biotech sphere reached new heights and researchers... Read more »

  During this Fall’s Genome Startup Day event, we welcomed researchers and entrepreneurs that have taken the plunge into commercializing their phage discoveries. John Eisen, PhD, UC Davis professor and renowned genomics and microbiology researcher, spoke with Ivan Liachko, PhD, Founder and CEO for Phase Genomics, for a candid and lively fireside chat on the... Read more »